Haili Biotechnology: Intends to acquire the remaining 41% equity of Ruisheng Biotechnology, after which its ownership will reach 96%.

Haili Biotech announced on December 12th that the company plans to acquire the remaining 41% equity of Shaanxi Ruisheng Biotechnology Co., Ltd. After this transaction is completed, the company's stake in Ruisheng Biotechnology will reach 96%. This transaction constitutes a related party transaction and does not constitute a major asset restructuring.